



HAL
open science

In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion

Andreza Rochelle, Vale Morais, André Leandro Silva, Andreza Rochelle Do Vale Morais, André Leandro Silva, Sandrine Cojean, Kaluvu Balaraman, Christian Bories, Sébastien Pomel, Gillian Barratt, et al.

► **To cite this version:**

Andreza Rochelle, Vale Morais, André Leandro Silva, Andreza Rochelle Do Vale Morais, André Leandro Silva, et al.. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion. *Experimental Parasitology*, 2018, 192, pp.85-92. 10.1016/j.exppara.2018.07.017 . hal-02370461

HAL Id: hal-02370461

<https://hal.science/hal-02370461v1>

Submitted on 19 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 ***In-vitro* and *in-vivo* antileishmanial activity of inexpensive Amphotericin B formulations:**
2 **heated Amphotericin B and Amphotericin B-loaded microemulsion**

3 **Running title: Antileishmanial activity of Amphotericin B formulations**

4 Andreza Rochelle do Vale Morais^{a,c}, André Leandro Silva^{b,c}, Sandrine Cojean^d, Kaluvu
5 Balaraman^{d,c}, Christian Bories^d, Sébastien Pomel^d, Gillian Barratt^c, Eryvaldo Sócrates Tabosa
6 do Egito^{a,b}, Philippe M Loiseau^{d#}

7 ^a Universidade Federal do Rio Grande do Norte (UFRN), Programa de Pós-graduação em
8 Nanotecnologia Farmacêutica, Rua Gustavo Cordeiro de Farias, SN. Petrópolis. CEP: 59012-
9 570 Natal/RN - Brazil.

10 ^b UFRN, Programa de Pós-graduação em Biotecnologia (RENORBIO), Av. Senador Salgado
11 Filho, 3000. Campus Universitário. CEP: 59078-970 Natal/RN - Brazil

12 ^c Université Paris-Sud, Institut Galien Paris-Sud, UMR-CNRS 8612, 5, Rue Jean-Baptiste
13 Clément, 92296 Châtenay-Malabry cedex, France.

14 ^d Université Paris-Sud, Faculté de Pharmacie, UMR 8076 CNRS BioCIS, Châtenay-Malabry,
15 France

16 ^e Chemical Biology Lab, Department of Biotechnology, IITM, Technology Madras, Chennai,
17 India

18

19

20 **#Corresponding author**

21 Prof. Philippe M. LOISEAU

22 philippe.loiseau@u-psud.fr

23 Antiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy, Université
24 Paris-Sud
25 Rue Jean-Baptiste Clément, F 92290- Chatenay-Malabry
26

27 **Abstract:**

28 Amphotericin B (AmB) is effective against visceral leishmaniasis (VL), but the renal toxicity
29 of the conventional form, mixed micelles with deoxycholate (M-AmB), is often dose-limiting,
30 while the less toxic lipid-based formulations such as AmBisome[®] are very expensive. Two
31 different strategies to improve the therapeutic index of AmB with inexpensive ingredients
32 were evaluated on this work: (i) the heat treatment of the commercial formulation (H-AmB)
33 and (ii) the preparation of an AmB-loaded microemulsion (ME-AmB). M-AmB was heated to
34 70°C for 20 min. The resulting product was characterized by UV spectrophotometry and
35 circular dichroism, showing super-aggregates formation. ME-AmB was prepared from
36 phosphate buffer pH 7.4, Tween 80[®], Lipoid S100[®] and Mygliol 812[®] with AmB at 5 mg/mL.
37 The droplet size, measured by dynamic light scattering, was about 40 nm and transmission
38 electron microscopy confirmed a spherical shape. Rheological analysis showed low viscosity
39 and Newtonian behavior. All the formulations were active *in vitro* and *in vivo* against
40 *Leishmania donovani* (LV9). A selectivity index (CC₅₀ on RAW/IC₅₀ on LV9) higher than 10
41 was observed for ME-AmB, H-AmB and AmBisome[®]. Furthermore, no important *in vivo*
42 toxicity was observed for all the samples. The *in-vivo* efficacy of the formulations after IV
43 administration was evaluated in Balb/C mice infected with LV9 (three doses of 1 mg/kg
44 AmB) and no significant difference was observed between H-AmB, M-AmB, ME-AmB and
45 AmBisome[®]. In conclusion, these two inexpensive alternative formulations for AmB showing
46 good efficacy and selectivity for *Leishmania donovani* merit further investigation.

47

48

49 INTRODUCTION

50 Leishmaniasis is a parasitic infectious disease caused by obligate intra-macrophage
51 protozoa of the *Leishmania* species, transmitted to humans via the bite of female sand flies of
52 the genera *Phlebotomus* and *Lutzomyia*. This disease is widespread in tropical and subtropical
53 areas as three different clinical manifestations: mucocutaneous, cutaneous, and visceral
54 leishmaniasis (VL), also known as kala-azar, which is fatal if untreated (1). Pentavalent
55 antimonials are the most commonly used drugs to treat VL; however, they are no longer
56 recommended due to their toxicity and the emergence of drug resistance (2). Amphotericin B
57 (AmB) and miltefosine are the two alternative drugs able to replace antimonials, although
58 neither drug is completely safe (3). This work is focused on the exploitation of AmB as low-
59 cost and low-toxic formulations.

60 AmB has been used as a second-line drug for leishmaniasis treatment (4). Despite its
61 high efficacy, toxic effects, such as cardiotoxicity and nephrotoxicity, limit its successful
62 therapeutic use. The AmB selectivity and toxicity level depend on its aggregation state, which
63 can exist as monomeric, aggregated and super-aggregated states. In order to reduce the side
64 effects credited to AmB, several lipid formulations have been developed. These systems
65 prevent the AmB self-aggregation and slowly release AmB monomers to the surrounding
66 medium (5). An example of success on the lipidic approach is the liposomal AmB formulation
67 (AmBisome[®]), which is less toxic than Fungizone[®], the commercial available micellar AmB
68 (M-AmB). Nevertheless, AmBisome[®] is not widely available due to its cost.

69 To summarize, the current visceral leishmaniasis treatment remains limited by the
70 issues of drug resistance, toxicity and high cost (6). The therapeutic properties and

71 pharmacological profile of AmB can be optimized by modifying the aggregation state of the
72 drug (7) and by developing new drug delivery systems.

73 M-AmB has good availability and relatively low cost; hence it is the most widely used
74 AmB-based product. However, the presence of AmB in the aggregated state allows the
75 formation of ion channels in membranes containing cholesterol, which causes toxicity (8).
76 Studies have shown that the heating of M-AmB is capable of inducing a new type of
77 aggregate, called super-aggregates, which is less selective for the cholesterol in the
78 mammalian cell membranes. Therefore, the toxicity can be significantly reduced without loss
79 of activity (5, 7, 9, 10). The molecular rearrangement that yields super-aggregate structures
80 can be achieved by appropriate heating of M-AmB (5, 11).

81 An alternative formulation without the drawbacks of cost and toxicity could be a
82 microemulsion (ME). Microemulsions are anisotropic, clear, small droplet sized and
83 thermodynamically stable drug delivery systems, comprised of an oil and aqueous phase,
84 stabilized by surfactants (12). The ME would be able to carry AmB (ME-AmB) in its
85 dispersed phase, increasing its solubilization and bioavailability, and decreasing its toxicity
86 (13, 14).

87 The aim of this work was to investigate Heated M-AmB (H-AmB) and ME-AmB in
88 comparison with M-AmB and AmBisome[®] with regard to their *in-vitro* and *in-vivo* safety and
89 antileishmanial activity against *Leishmania donovani*, in order to improve the therapeutic
90 index of AmB while using inexpensive ingredients.

91

92

93 MATERIALS AND METHODS

94 Chemicals

95 Micellar AmB (Anforicin B[®]) was a gift from Cristália (Itapira, Brazil). Liposomal
96 AmB (AmBisome[®]) was purchased from Gilead (Foster City, USA). Miglyol[®] 812, used as
97 the oil phase of the ME, was obtained from CONDEA Chemie GMBH (Hamburg, Germany).
98 Lipoid[®] S100, used as surfactant, was purchased from LIPOID GMBH (Ludwigshafen,
99 Germany). The AmB, used to load the ME, Tween[®] 80, used as surfactant, NaH₂PO₄ and
100 Na₂HPO₄, used to prepare the phosphate buffer pH 7.4, were all acquired from Sigma Aldrich
101 Inc (St. Louis, USA).

102 Sample preparation

103 AmBisome[®] was prepared according to the manufacturer's instructions. The
104 commercial M-AmB was prepared by adding 10 mL of water for injection into the vial
105 containing 50 mg of AmB (final concentration of 5×10^{-3} M), followed by vortex shaking until
106 dissolution. In order to obtain the H-AmB, the M-AmB was heated at 70°C for 20 min.

107 In order to prepare the ME, 68 %_(w/w) of phosphate buffer pH 7.4, 14.7 %_(w/w) of
108 Tween[®] 80, 6.3 %_(w/w) of Lipoid[®] S100 and 11 %_(w/w) of Miglyol[®] 812 were weighed. They
109 were mixed under magnetic stirring followed by 3 cycles of probe sonication (80 watts power
110 output) in a Branson Digital Sonifier S-250 (Branson Ultrasonic Corporation – Danbury,
111 USA) for 1.5 min and followed by 3 min in a 1210E-MTH Bransonic Ultrasonic bath
112 (Branson Ultrasonic Corporation – Danbury, USA). To incorporate AmB into the ME, solid
113 AmB was added to a final concentration of 5×10^{-3} M. Then, the system was alkalized with

114 NaOH 1M until complete AmB solubilization. After that the loaded ME was neutralized by
115 addition of HCl 1M to a final pH of 7.4.

116 **M-AmB and H-AmB characterization**

117 AmB molecules exhibit absorbance bands correlated to their aggregation state in the
118 UV/Vis range of 300 to 450 nm. A PerkinElmer Lambda 25 UV/VIS spectrometer (Waltham,
119 MA, USA) was used to analyze AmB-containing samples in 1cm path length cuvettes.
120 Samples were diluted in pure water and analyzed immediately after dilution. M-AmB and H-
121 AmB were diluted to 5×10^{-6} M of AmB (5, 13).

122 Circular dichroism (CD) spectra were recorded with a Jasco J-180 dichrograph
123 (Easton, MD, USA). Samples were diluted in water to $5 \cdot 10^{-5}$ M AmB 24h before analysis.
124 Measurements were conducted at room temperature using a 0.1 cm path length cuvette (15).
125 Results are expressed as $\Delta\epsilon$ (differential molar absorption dichroic coefficient).

126 **Microemulsion characterization**

127 Droplet size distribution analyses were carried out by Dynamic Light Scattering (DLS)
128 using a Malvern-Zetasizer Nano ZS (Malvern, UK). Transmission electron microscopy
129 (TEM) was used to investigate the ME morphology. The MEs was observed after staining
130 with 2% phosphotungstic acid, using a JEOL 1400 apparatus (SamXPlus, France), operated at
131 80kV as the acceleration voltage, equipped with a high resolution CCD Gatan digital camera
132 (SC1000 Orius, France). Before performing both types of analysis, the MEs were diluted 1:20
133 with water.

134 The rheological properties of the MEs were evaluated by a Haake Rheo Stress 600
135 rheometer equipped with 35mm cone-plate geometry (Thermo Scientific, USA). The flow

136 curve and the viscosity curve of the samples were performed by controlled shear rate rotation
137 tests (from 0.1 s⁻¹ to 1000 s⁻¹).

138 The aggregation state of the AmB in the ME-AmB was also evaluated by
139 spectrophotometry and CD as described above.

140 ***In vitro* antileishmanial activity**

141 The promastigote stages of *Leishmania donovani* (MHOM/IN/80/DD8) wild-type and
142 of the AmB-resistant (AmB-R) strain obtained from the wild-type parasites by *in-vitro* drug
143 pressure were grown in M-199 medium supplemented with 40 mM HEPES, 100 μM
144 adenosine, 0.5 mg/L haemin, and 10% heat-inactivated fetal bovine serum (FBS) at 26 °C in a
145 dark environment under an atmosphere of 5 % CO₂. Parasites in their logarithmic phase of
146 growth were used for all experiments. Promastigotes were grown at 37 °C in 5% CO₂
147 atmosphere for 24 hours before treatment for differentiation. The axenic amastigotes were
148 generated by differentiation of promastigotes. To achieve this, a 1 × 10⁶ promastigote
149 suspension was diluted in 5mL of axenic amastigote media (1 X M-199, 40 mM HEPES, 100
150 μM adenosine, 0.5 mg/L haemin, 2 mM CaCl₂, 2 mM MgCl₂ and 20% FBS) and the pH was
151 adjusted to pH 6.

152 *Evaluation of the in vitro antileishmanial activity on axenic amastigote stage*

153 Axenic amastigotes were suspended at 5 x 10⁶ cells/mL in a final volume of 200 μL.
154 Serial dilutions from 100 to 0.39 μg AmB/mL was performed by distributing AmBisome[®], M-
155 Amb, H-AmB, ME-AmB, and ME in 96-well plates. Triplicates were used for each
156 concentration. The viability of the axenic amastigote stage was assessed using the trypan blue
157 exclusion method after a 3-day incubation period at 37 °C, in the dark, under a 5% CO₂

158 atmosphere. Parasite growth was determined by using SYBR Green I (Invitrogen, France), a
159 dye whose fluorescence is greatly enhanced upon contact with the parasite DNA. The plates
160 were frozen 3 times and the DNA was extracted from the plates according to the Direct PCR
161 (cell) protocol (Viagen Biotech Inc, Eurogentec, France). Into the PCR plate 10 μ L of Lysate
162 and 40 μ L of direct PCR (cell) supplemented with SYBR green I (5 μ L of SYBR Green I / 10
163 mL of lysis buffer) were added. Untreated parasites were used as control. The fluorescence
164 was directly evaluated on a Mastercycler[®] ep realplex real-time PCR system (Eppendorf,
165 France). The program was as follows: 90 °C, 1 min and ramp time of 5 min to obtain 10 °C,
166 during this period the fluorescence was obtained in continue and in a hold step at 10 °C. The
167 curves of fluorescence were analyzed and the fluorescence at 10°C was used to determine the
168 concentrations inhibiting parasite growth by 50 % (IC₅₀). Indeed, the IC₅₀, the concentration
169 inhibiting the parasite growth by 50%, was determined using the software in line at
170 <http://www.antimalarial-icestimator.net/MethodIntro.htm>.

171 *Evaluation of the in vitro antileishmanial activity on intramacrophagic amastigotes*

172 RAW 264.7 cells (mouse leukemic monocyte macrophage cells) cultured in DMEM
173 with L-glutamine (Life technologies) and 10% FBS (Life technologies) were suspended to
174 yield 1.5 x 10⁵ cells/mL in 96-well plate, in a final volume of 100 μ L. After a 24 h incubation
175 period, cells were infected by a suspension of 1 x 10⁶ *Leishmania donovani* axenic
176 amastigotes/mL in DMEM, and incubated for 24 h at 37 °C in the dark and under a 5 % CO₂
177 atmosphere. The free parasites were, then, eliminated by washing and intramacrophagic
178 amastigotes were treated with the same AmB samples and concentrations as those in the assay
179 on axenic amastigotes. After 48 h of incubation under the same conditions, the experiment
180 was stopped and the plate was treated as for the axenic amastigote stage assay. Each
181 experiment was performed in triplicate (16). Fluorescence was compared to that obtained with

182 untreated infected and uninfected macrophages and untreated axenic parasites used as
183 controls.

184 ***In-vivo* evaluation**

185 All procedures involving animals were conducted in compliance with the standards for
186 animal experiments and were approved by the local committee for animal care (0858.01/2014,
187 Versailles, France).

188 ***In-vivo* antileishmanial activity**

189 A suspension of *Leishmania donovani* (LV9) amastigotes ($1 \times 10^7/100 \mu\text{L}$ M199
190 medium supplemented with 40 mM HEPES, 100 μM adenosine and 0.5 mg/L haemin, 10%
191 FBS), obtained from infected hamster spleen, was injected into female BALB/c mice
192 (weighing 20 g) by intravenous route. The mice were randomly sorted into six groups seven
193 days after the infection. Each group was treated with 100 μL of one formulation
194 (AmBisome[®], M-AmB, H-AmB, ME-AmB and ME), administered by intravenous route for 3
195 alternate days (1mg/kg/day). Samples were diluted prior to use with 5% glucose to give a final
196 AmB concentration of 2×10^{-4} M. Animals were sacrificed three days after the end of
197 treatment. Livers and spleens were weighed and drug activity was estimated microscopically
198 by counting the number of amastigotes/500 liver cells in Giemsa stained impression smears to
199 calculate the *Leishmania donovani* units (LDU) for liver parasite burdens, using the Stauber's
200 formula (17). The mean number of parasites per gram of liver among treatment groups and
201 controls was compared. Three independent counting were performed and the results were
202 expressed as the mean values \pm SD. The parasite burden of treatment groups and controls

203 were compared using the Kruskal–Wallis nonparametric analysis of variance test for
204 comparing two groups. Significance was established for a P value < 0.05.

205 ***In vitro* cytotoxicity assay**

206 RAW 264.7 cells maintained in DMEM supplemented with 10% of heat-inactivated
207 FBS (Life technologies) were seeded to early confluence in a 96-well plate at density of 7500
208 cell/well and incubated in 5 % CO₂ at 37 °C for 24 h in a final volume of 100 µL. Thereafter,
209 M-AmB, H-AmB, ME-AmB, AmBisome[®] and ME were added to achieve final AmB
210 concentrations from 0.1 to 108 µM and incubated for a further 24 h under the same
211 conditions. In order to estimate background absorbance due to light scattering, wells without
212 cells, but containing the same concentration of the samples, were analyzed. The cytotoxicity
213 of the formulations was evaluated using the MTS [3-(4,5-dimethyl-2-yl)-5-(3-
214 carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay, whereupon 20
215 µL of MTS solution were added into the wells and incubated for further 2 h. Finally, the
216 absorbance was measured using a 492-nm high-pass filter in a Multiskan MS microwell plate
217 reader (Labsystem, Ramat-Gan, Israel) and the IC₅₀ for each formulation was calculated. For
218 this assay 4 replicates were performed.

219 ***In vivo* toxicity assay**

220 Blood samples taken from the mice from the antileishmanial activity experiment were
221 kept at room temperature for about 30 min and, then, centrifuged at 3,500 g for 10 min. In
222 order to evaluate the renal and liver toxicity, serum was harvested from each blood sample
223 and total serum cholesterol (CHO), alkaline phosphatase (ALP), aspartate aminotransferase

224 (AST), alanineaminotransferase (ALT), creatinine (CREA) and urea (URE) concentrations
225 were determined by commercially available kits according to the manufacturer's instruction.

226 **Statistical analysis**

227 Statistical analyses were performed by using analysis of variance or Kruskal-Wallis tests
228 (nonparametric), followed by the Tukey's or the Dunn's multiple comparison test. GraphPad
229 Prism5 version (GraphPad Software Inc., La Jolla, CA) was used to perform the analysis.
230 Significance was established for a P value < 0.05.

231

232 **RESULTS**

233 **M-AmB and H-AmB characterization**

234 The UV-Vis spectrum for M-AmB (Figure 1a) showed four main peaks at 329, 367, 388 and
235 408 nm. The first peak is credited to the aggregated form of AmB whereas the one at 408 is
236 ascribed to the monomeric form (15). After heat treatment it was observed that H-AmB
237 (Figure 1a) presented similar peaks to M-AmB regarding the monomeric form, but the
238 aggregate-related peak underwent a blue shift and became centered on 323 nm in this
239 preparation. The UV-Vis results were in accordance with those observed by circular
240 dichroism (Figure 1c), in which the doublet related to the AmB aggregation was also blue-
241 shifted for H-AmB.

242 **Microemulsion characterization**

243 The produced ME was optically clear with a mean droplet size of 22 nm for the
244 unloaded ME and 36 nm for the ME containing AmB, with polydispersity indexes of 0.170
245 and 0.594, respectively, indicating that the addition of AmB led to slightly larger particles.
246 TEM revealed that the droplets were spherical in shape even after the addition of AmB
247 (Figure 2). Furthermore, the average size was similar to the DLS results. The rheological
248 analysis revealed that both the unloaded ME and the ME containing AmB (Figure 3) showed
249 a linear relationship between shear stress and shear rate, which is characteristic of a
250 Newtonian material. The apparent viscosity of the unloaded ME and ME containing AmB
251 were $0.0623 \text{ Pas} \pm 0.0101$ and $0.1141 \text{ Pas} \pm 0.0049$, respectively, which is low because the
252 ME was of the oil-in-water type. The low viscosity would ensure good syringeability as well
253 as ease of mixing with intravenous fluids using minimum mechanical agitation. The AmB

254 molecule showed to be in both aggregated and monomeric forms (Figure 1b and 1d), since
255 peaks at 323 nm (aggregated form), 367, 388 and 408 nm (monomeric form) were observed.
256 All these results: the small spherical droplet size, the transparency and the low viscosity,
257 allow these samples to be characterized as a true ME system. The incorporation of AmB did
258 not affect these parameters.

259 **Toxicity of the formulations**

260 The CC_{50} was evaluated *in vitro* for each formulation (Table 1). M-AmB showed high
261 toxicity towards RAW cells ($CC_{50} 4.5 \pm 0.4 \mu\text{M}$). However, when this formulation was heated
262 this value increased approximately 8-folds to $39.8 \pm 3.2 \mu\text{M}$, indicated a decrease in toxicity.
263 In fact, in this study, the toxicity of H-AmB was similar to that of AmBisome[®]. On the other
264 hand, although the incorporation of the AmB into the ME decreased the CC_{50} of the
265 formulation compared to the unloaded ME, the cytotoxic effect of ME-AmB ($CC_{50} 9.0 \pm 0.3$)
266 was slightly lower than that of M-AmB.

267 The results of the evaluation of the toxicity *in vivo* are given in Table 2. There were no
268 significant changes ($p > 0.05$) among the samples for the two transaminase activities levels
269 (AST and ALT) and the creatinine levels. However, all treatments caused a significant
270 increase ($P < 0.05$) in the urea level except for mice treated with unloaded ME. A significant
271 decrease in this parameter was also observed in the mice treated with the ME and the ME-
272 AmB compared to the AmBisome[®]. Furthermore, it is noteworthy that heating of M-AmB
273 slightly decreased the blood urea levels. The ALP value increased significantly with all
274 treatments compared to the untreated group. Nevertheless, the ALP level for the mice treated
275 with the AmBisome[®] was significantly lower than that of the mice treated with the ME-AmB.
276 The CHO results showed no difference between the ME, the AmBisome[®] and the untreated

277 group. However, M-AmB, H-AmB and ME-AmB caused a significant decrease in this
278 parameter, while the lowest values were observed in the mice treated with the ME-AmB.

279 **Antileishmanial activity**

280 The activity of the formulations against *Leishmania donovani* was evaluated *in vitro*
281 and *in vivo*. The *in-vitro* assays were performed on both Wild-type (WT) and AmB-R
282 intramacrophagic and axenic amastigotes (Table 1). All formulations, except ME (unloaded
283 microemulsion), showed high activity against WT parasites. ME-AmB and H-AmB yielded
284 lower IC₅₀ values than the AmBisome[®] for both amastigote stages. As far as the activity on
285 axenic amastigotes was concerned, all the formulations exhibited lower IC₅₀ compared to the
286 intramacrophage amastigote. However, the IC₅₀ of the AmBisome[®] did not change
287 significantly (1.73 μM and 1.76 μM).

288 The H-AmB showed a higher IC₅₀ than the M-AmB, when the *Leishmania* was within
289 macrophage, and similar antileishmanial activity (IC₅₀ = 0.05 μM) against the axenic stage.
290 However, the selectivity index for the H-AmB was approximately 3-fold higher than that of
291 the M-AmB. Moreover, the ME-AmB showed a better selectivity index than the M-AmB,
292 although it remained lower than the AmBisome[®].

293 Some clinical isolates of *Leishmania donovani* have shown resistance against the AmB
294 (18). Therefore, the issue of AmB resistance should be considered early in the development of
295 any new AmB delivery system. With this in mind, the formulations were evaluated against
296 both AmB-resistant axenic and intramacrophagic amastigotes. The AmBisome[®] was active
297 against AmB-resistant intramacrophage amastigotes, but it did not show any activity on AmB-
298 resistant axenic amastigote. On the other hand, the other formulations were active in a range
299 from 0.8 to 4 μM on both axenic and intramacrophagic amastigotes. The drug pressure to get
300 the AmB-R line was previously carried out using M-AmB. Indeed, the IC₅₀ value of M-AmB

301 on the AmB-R line was about 30 times higher than those of the WT, both on axenic and
302 intramacrophage amastigotes. Interestingly, the IC₅₀ values of H-AmB, AmBisome® and ME-
303 AmB on the AmB-R intramacrophage amastigotes were only about twice as high as those on
304 the WT. These results suggest that these formulations could be useful for the treatment of
305 AmB-R leishmaniasis.

306 The *in-vivo* antileishmanial evaluation was performed on the *Leishmania*
307 *donovani*/Balb/C mice model. The percentage of parasite burden reduction *in vivo* is shown in
308 the Table 2. Whereas the unloaded ME alone did not show good activity *in vivo*, M-AmB, H-
309 AmB, ME-AmB and AmBisome® all reduced the parasite burden greatly, with no significant
310 difference between the formulations. No sign of acute toxicity was observed in the mice and
311 the biological parameters did not show significant toxicity, as shown in Table 2.

312

313 **DISCUSSION**

314 The MEs prepared in this study showed a spherical shape and a small droplet size,
315 which is in agreement with other studies that describe these systems as having diameters less
316 than 150 nm (12, 14). Although the addition of AmB to the ME increased its droplet size,
317 probably due to the large molecule size and its deposition on the ME interface, the ME-AmB
318 droplet size remained within the acceptable range. Such small droplets on MEs produce only
319 weak scattering of visible light, and as a result the system is transparent, as observed
320 macroscopically in this work. Moreover, the probability of embolus formation after injection
321 of MEs is insignificant due to their small droplet size (12).

322 Since the nanosized droplets do not interact with each other, the resulting MEs have
323 low viscosity (19). The viscosity analysis is of utmost importance since the parenteral
324 administration of very viscous samples could be painful for the patient. Furthermore, it is well
325 known that the syringeability is affected by the viscosity of the parenteral formulations (20).

326 The ME and ME-AmB showed a constant low viscosity and proportionality between shear
327 stress and shear rate, for which they were deemed to behave as Newtonian fluids. As a
328 consequence, they can be considered suitable for the intravenous route. This low viscosity
329 ensures ease of mixing with intravenous fluids with minimum mechanical agitation as well as
330 good syringeability and, therefore, can ensure good patient compliance.

331 Spectrophotometric studies revealed that after the heating process, super-aggregates
332 are formed from M-AmB, manifested as a blue-shift in the electronic spectra as well as a
333 decrease on the dichroic doublet, which is also blue-shifted in the spectra of H-AmB (15).
334 When AmB was loaded into the ME, a pattern similar to H-AmB was observed. Since the
335 system was not heated in order to form AmB super-aggregates, the peak at 323 nm probably
336 represents the association of the AmB with the ME-oil phase. Pham et al, (2014) (21) have
337 shown blue-shifts in the AmB dichroic doublet when the molecule is loaded into liposomes.
338 Our results are in agreement with Silva et al (2013) (22), who have developed ME systems to
339 carry AmB and have demonstrated peaks of AmB aggregates and monomers at the same time.
340 However, the aggregate peak is not the same as one observed in our work, supporting the
341 theory of that such a peak is a result of a complex formed between the molecule and the
342 system, which for instance depends on the used raw material, mainly the surfactants. Larabi et
343 al (2004) (23) reported studies in which absorption spectrum and circular dichroism varied
344 according to the proportion of lipid in the formulation. Knowing the aggregation state of the
345 molecule inside the carrier is very important since it influences the drug efficacy and toxicity
346 (5, 9, 13, 15, 24).

347 The treatment of visceral leishmaniasis was dominated by pentavalent antimonials for
348 a long time. However due to their toxicity and adverse side effects, these drugs have
349 progressively been replaced as the first-line treatment by the AmB, which is considered as the
350 best existing drug against this disease. Among the different commercial formulations,

351 Fungizone[®] (a mixture of AmB with deoxycholate in a phosphate buffer) is the most
352 frequently used. However, the liposomal formulation is the most effective and safe, despite its
353 high cost (4).

354 In this work, we have proposed two new formulations of AmB which retain its activity
355 while reducing its toxicity, and are furthermore inexpensive, with costs accessible for patients
356 from the tropical endemic countries and easy to manufacture. Both H-AmB and ME-AmB
357 were thoroughly characterized and shown to be appropriate for parenteral use against visceral
358 leishmaniasis. In order to investigate the antileishmanial activity of these formulations, their
359 IC₅₀ in axenic and intramacrophage amastigote were evaluated *in vitro*, as well as the
360 percentage of reduction of parasite burden *in vivo*. In addition, the cytotoxicity of the
361 formulations was examined *in vitro*, allowing calculation of the Selectivity Index, while the
362 toxic effects *in vivo* were analyzed by assessment of renal and liver function, because the most
363 serious side effect of AmB is nephrotoxicity (25).

364 Both *in-vitro* and *in-vivo* experiments with the WT line demonstrated that, as expected,
365 all formulations containing AmB were effective against *Leishmania donovani*. On the other
366 hand, despite a moderate effect *in-vitro*, unloaded ME did not show significant *in-vivo*
367 antileishmanial activity, proving that it was the addition of AmB that produced this effect.

368 Some differences in the *in-vitro* effectiveness were observed when comparing the
369 axenic and intramacrophagic amastigotes. The axenic amastigote assay allowed us to evaluate
370 an intrinsic activity on parasites, whereas the intramacrophage amastigote assay demonstrates
371 the ability of the active drug to be delivered through the macrophage membrane, the
372 parasitophorous vacuole membrane and finally into the parasite (26, 27). It is noteworthy that
373 AmBisome[®] was not active against AmB-R axenic amastigotes while the other formulations
374 did have some activity. This result cannot be a result of the ME diameter being less than that
375 of AmBisome[®] (35 vs 80 nm, respectively) since H-AmB, AmBisome[®] and ME-AmB had

376 similar activities on the WT intramacrophage amastigotes. This observation could be related
377 to the composition of the AmB-R membranes, poor in sterols, more fluid than the WT
378 membranes and, therefore, more stable and less sensitive to a liposomal effect. With the
379 intramacrophagic amastigotes, this difference was not observed since all the formulations
380 after macrophage phagocytosis released AmB within the parasitiphorous vacuole, probably
381 after fusing with lysosomes. Indeed, AmBisome® is a very stable formulation with
382 cholesterol and a high-transition-temperature phosphatidylcholine making a very impermeable
383 membrane and phosphatidylglycerol forming an electrostatic complex with AmB. It is
384 possible that parasite-derived enzymes are necessary to release the AmB from the liposomes
385 and that the AmB-R parasites have a different enzyme profile and are less efficient at this. On
386 the other hand, AmB may be less strongly associated in M-AmB, H-AmB and ME-AmB.
387 Further studies could be focused on the ME behaviour within the infected macrophages
388 through confocal studies.

389 M-AmB showed the lowest selectivity index, while H-AmB presented the highest
390 index. Therefore, the heating process was capable of considerably reducing the cytotoxicity of
391 AmB *in vitro* as demonstrated by the CC₅₀ values. This result is supported by Gaboriau et al.
392 (1997)(28) and Petit et al. (1998) (10) whose have found the mild heating as a simple way to
393 decrease the toxicity of micellar AmB systems. In addition, the therapeutic window between
394 the IC₅₀ (1.53 µM) and CC₅₀ (39.8 µM) of H-AmB is wider than that of M-AmB, thus
395 improving its safety. It is interesting to mention that H-AmB have shown to favor drug uptake
396 by macrophage-like cell line (9). The authors suggest that this fact could be interesting since
397 the macrophage could act as a reservoir, releasing monomeric AmB on the infection site and,
398 thus, improving antiparasitic effect (9). ME-AmB (selectivity index = 10.23) also showed a
399 better selectivity compared to M-AmB. When the selectivity index is greater than 10, it is
400 generally, considered that the pharmacological efficacy is not due to the *in-vitro* cytotoxicity

401 (29), therefore, the incorporation of AmB in ME systems was able to improve the
402 effectiveness of the drug.

403 The potential of the new formulations (H-AmB and ME-AmB) was confirmed by the
404 *in-vivo* studies, which showed no significant differences in their ability to reduce the parasite
405 burden compared to the AmBisome[®]. In addition, both formulations demonstrated minimal
406 cytotoxicity *in vivo*.

407 The biochemical evaluation of kidney and liver parameters showed that the untreated
408 infected mice had lower values than those with no parasite burden (reference values were
409 found in (30). Some studies have described a reduction of the serum cholesterol
410 concentrations as a function of the splenic parasite burden, since this organ is responsible for
411 cholesterol biosynthesis (31). An overview of all the biochemical results showed that despite
412 some values, which were statistically different, there was a minimal variation among the
413 groups, showing that none of the formulations induced toxicity at the doses used in this study.
414 Therefore, ME-AmB and H-AmB were considered safe regarding the limited damage to
415 macrophage and the *in vivo* evaluation.

416 Furthermore, ME-AmB, M-AmB and H-AmB showed efficiency against AmB-R
417 intramacrophagic amastigotes. AmB-unresponsive cases have been reported at the Rajendra
418 Memorial Research Institute of Medical Sciences (RMRIMS), Bihar, India. These drug-
419 resistant cases are to be expected due to the very high frequency of AmB use (18). Since
420 visceral leishmaniasis is fatal, the development of new systems, which do not demonstrate
421 drug resistance is very important to ensure that suitable treatment would be available.
422 Therefore, these two inexpensive alternative formulations for AmB showing good efficacy
423 and selectivity for *Leishmania donovani* merit further investigation. Unfortunately, it was not
424 possible to verify the *in-vivo* efficacy of the formulations on an AmB-R/ mice model since the
425 AmB-R parasites are poorly infectious for Balb/c mice (32).

426 **CONCLUSION**

427 These experiments show a novel approach to AmB therapy, addressing both the cost of
428 formulations and the AmB-resistance. The formulations H-AmB and ME-AmB proved to be
429 very successful in the treatment of a *Leishmania donovani* Balb/c mouse model. Both *in-vivo*
430 and *in-vitro* evaluations showed good efficacy and low toxicity for these formulations. Since
431 the method of preparing the H-AmB is just the heating of the reconstituted M-AmB for a few
432 minutes, it appears to be a low cost alternative to the commercially available products. The
433 cost of producing MEs is also lower than that of producing the liposomal AmB, since the
434 components are commonly used pharmaceutical excipients rather than expensive
435 phospholipids. Therefore, the formulation developed in this work is a promising way to
436 reduce toxicity while maintaining the efficacy of AmB.

437 **ACKNOWLEDGEMENTS:**

438 The authors wish to thank the CAPES-Cofecub and CNPq for the financial support. Kaluvu
439 Balaraman was recipient of a post-doctoral fellowship grant No 4803-04 from CEFIPRA. The
440 authors would like to acknowledge Dr. Phuong-Nhi Bories, Hôpital Cochin, Paris, for the
441 measurement of the toxicity markers. The authors are grateful to Dr. Claire Boulogne and Dr
442 Cynthia Gillet, IMAGIF Platform, Gif-sur-Yvette for measurement of the TEM, and Nicolas
443 Huangand and Monique Chéron for the help during the rheological and dichroism analysis,
444 respectively.

445

446 **REFERENCES**

- 447 1. **Kevric I, Cappel MA, Keeling JH.** 2015. New world and old world Leishmania infections: A
448 Practical Review. *Dermatol Clin* **33**:579-593.
- 449 2. **Frézard F, Monte-Neto R, Reis P.** 2014. Antimony transport mechanisms in resistant
450 leishmania parasites. *Biophys Rev* **6**:119-132.
- 451 3. **No JH.** 2016. Visceral leishmaniasis: Revisiting current treatments and approaches for future
452 discoveries. *Acta Trop* **155**:113-123.
- 453 4. **Chattopadhyay A, Jafurulla M.** 2011. A novel mechanism for an old drug: amphotericin B in
454 the treatment of visceral leishmaniasis. *Biochem Biophys Res Commun* **416**:7-12.
- 455 5. **Silva MA, Siqueira SDVD, Freire LB, Araujo IB, Silva KGDE, Medeiros AD, Araujo I, Oliveira
456 AG, Egito EST.** 2012. How can micelle systems be rebuilt by a heating process? *Int J*
457 *Nanomedicine* **7**:141-150.
- 458 6. **Dea-Ayuela MA, Rama-Iniguez S, Sanchez-Brunete JA, Torrado JJ, Alunda JM, Bolas-
459 Fernandez F.** 2004. Anti-leishmanial activity of a new formulation of amphotericin B. *Trop*
460 *Med Int Health* **9**:981-990.
- 461 7. **Petit C, Yardley V, Gaboriau F, Bolard J, Croft SL.** 1999. Activity of a heat-induced
462 reformulation of amphotericin B deoxycholate (fungizone) against *Leishmania donovani*.
463 *Antimicrob Agents Chemother* **43**:390-392.
- 464 8. **Huang W, Zhang Z, Han X, Tang J, Wang J, Dong S, Wang E.** 2002. Ion channel behavior of
465 Amphotericin B in sterol-free and cholesterol- or ergosterol-containing supported


- 466 phosphatidylcholine bilayer model membranes investigated by electrochemistry and
467 spectroscopy. *Biophys J* **83**:3245-3255.
- 468 9. **Cheron M, Petit C, Bolard J, Gaboriau F.** 2003. Heat-induced reformulation of amphotericin
469 B-deoxycholate favours drug uptake by the macrophage-like cell line J774. *J Antimicrob*
470 *Chemother* **52**:904-910.
- 471 10. **Petit C, Cheron M, Joly V, Rodrigues JM, Bolard J, Gaboriau F.** 1998. In-vivo therapeutic
472 efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin
473 B obtained by mild heating. *J Antimicrob Chemother* **42**:779-785.
- 474 11. **Stoodley R, Wasan KM, Bizzotto D.** 2007. Fluorescence of amphotericin B-deoxycholate
475 (fungizone) monomers and aggregates and the effect of heat-treatment. *Langmuir* **23**:8718-
476 8725.
- 477 12. **Date AA, Nagarsenker MS.** 2008. Parenteral microemulsions: an overview. *Int J Pharm*
478 **355**:19-30.
- 479 13. **Damasceno BPGL, Dominici VA, Urbano IA, Silva JA, Araujo IB, Santos-Magalhaes NS, Silva**
480 **AKA, Medeiros AC, Oliveira AG, Egito EST.** 2012. Amphotericin B microemulsion reduces
481 toxicity and maintains the efficacy as an antifungal product. *J Biomed Nanotechnol* **8**:290-
482 300.
- 483 14. **Silveira WLL, Damasceno BPGL, Ferreira LF, Ribeiro ILS, Silva KS, Silva AL, Giannini MJM,**
484 **Silva-Júnior AA, Oliveira AG, Egito EST.** 2016. Development and characterization of a
485 microemulsion system containing Amphotericin B with potential ocular applications. *Curr*
486 *Neuropharmacol* **14**:1-1.

- 487 15. **Gaboriau F, Chéron M, Leroy L, Bolard J.** 1997. Physico-chemical properties of the heat-
488 induced 'superaggregates' of amphotericin B. *Biophys Chem* **66**:1-12.
- 489 16. **Audisio D, Messaoudi S, Cojean S, Peyrat JF, Brion JD, Bories C, Huteau F, Loiseau PM,**
490 **Alami M.** 2012. Synthesis and antikinoplastid activities of 3-substituted quinolinones
491 derivatives. *Eur J Med Chem* **52**:44-50.
- 492 17. **Stauber LA.** 1958. Host resistance to the Khartoum strain of *Leishmania donovani*. Rice
493 Institute Pamphlet - Rice University Studies. **45**(80 - 96).
- 494 18. **Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, Pandey K, Ravidas V, Kumar M, De**
495 **T, Singh D, Das P.** 2012. Mechanism of amphotericin B resistance in clinical isolates of
496 *Leishmania donovani*. *Antimicrob Agents Chemother* **56**:1031-1041.
- 497 19. **Lawrence MJ, Rees GD.** 2000. Microemulsion-based media as novel drug delivery systems.
498 *Adv Drug Deliv Rev* **45**:89-121.
- 499 20. **Jain J, Fernandes C, Patravale V.** 2010. Formulation development of parenteral phospholipid-
500 based microemulsion of etoposide. *AAPS PharmSciTech* **11**:826-831.
- 501 21. **Pham TTH, Gueutin C, Cheron M, Abreu S, Chaminade P, Loiseau PM, Barratt G.** 2014.
502 Development of antileishmanial lipid nanocomplexes. *Biochimie* **107**:143-153.
- 503 22. **Silva AE, Barratt G, Cheron M, Egito EST.** 2013. Development of oil-in-water microemulsions
504 for the oral delivery of amphotericin B. *Int J Pharm* **454**:641-648.
- 505 23. **Larabi M, Gulik A, Dedieu JP, Legrand P, Barratt G, Cheron M.** 2004. New lipid formulation
506 of amphotericin B: spectral and microscopic analysis. *BBA Biomembranes* **1664**:172-181.

- 507 24. **Starzyk J, Gruszecki M, Tutaj K, Luchowski R, Szlajak R, Wasko P, Grudzinski W, Czub J,**
508 **Gruszecki WI.** 2014. Self-association of Amphotericin B: Spontaneous formation of molecular
509 structures responsible for the toxic side effects of the antibiotic. *J Phys Chem B* **118**:13821-
510 13832.
- 511 25. **Fanos V, Cataldi L.** 2000. Amphotericin B-induced nephrotoxicity: a review. *J Chemother*
512 **12**:463-470.
- 513 26. **De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, Joshi D, Cameron S, Gilbert IH,**
514 **Wyatt PG, Frearson JA, Fairlamb AH, Gray DW.** 2013. Comparison of a high-throughput high-
515 content intracellular *Leishmania donovani* assay with an axenic amastigote assay. *Antimicrob*
516 *Agents Chemother* **57**:2913-2922.
- 517 27. **De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH.** 2011. A screen against
518 *Leishmania* intracellular amastigotes: comparison to a promastigote screen and identification
519 of a host cell-specific hit. *PLoS Negl Trop Dis* **5**:e1253.
- 520 28. **Gaboriau F, Cheron M, Petit C, Bolard J.** 1997. Heat-induced superaggregation of
521 amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index.
522 *Antimicrob Agents Chemother* **41**:2345-2351.
- 523 29. **Sarr SO, Perrotey S, Fall I, Ennahar S, Zhao M, Diop YM, Candolfi E, Marchioni E.** 2011.
524 *Icacina senegalensis* (Icacinaceae), traditionally used for the treatment of malaria, inhibits in
525 vitro *Plasmodium falciparum* growth without host cell toxicity. *Malar J* **10**:85.
- 526 30. **Vieira NC, Herrenknecht C, Vacus J, Fournet A, Bories C, Figadere B, Espindola LS, Loiseau**
527 **PM.** 2008. Selection of the most promising 2-substituted quinoline as antileishmanial
528 candidate for clinical trials. *Biomed Pharmacother* **62**:684-689.

- 529 31. **Gatto M, Abreu MM, Tasca KI, Simao JC, Fortaleza CM, Pereira PC, Calvi SA.** 2013.
530 Biochemical and nutritional evaluation of patients with visceral leishmaniasis before and
531 after treatment with leishmanicidal drugs. *Rev Soc Bras Med Trop* **46**:735-740.
- 532 32. **Mbongo N, Loiseau PM, Billion MA, Robert-Gero M.** 1998. Mechanism of amphotericin B
533 resistance in *Leishmania donovani* promastigotes. *Antimicrob Agents Chemother* **42**:352-357.
- 534
- 535
- 536
- 537
- 538
- 539
- 540
- 541
- 542

1



2


3

4 **Figure 1:** Spectroscopy of M-AmB and H-AmB (a) and of ME-AmB (b) and circular
5 dichroism of M-AmB and H-AmB (c) and of ME-AmB (d).

6

1

2



3


4 **Figure 2:** Transmission electronic microscopy of ME (a) and ME containing AmB (b).

5

1

2

3



4

5

Figure 3: Rheological behavior of ME and ME containing AmB.

6

7

8

9

10

1 **Table 1:** *In vitro* evaluation of the cytotoxicity and the anti-leishmanial activity on *L. donovani* WT and AmB-R.

Formulations	Intramacrophage amastigotes IC ₅₀ (μM) ± SD		Axenic amastigotes IC ₅₀ (μM) ± SD		Cytotoxicity RAW 264.7 macrophages CC ₅₀ (μM) ±SD	Selectivity index SI= CC ₅₀ /IC ₅₀
	WT	AmB-R	WT	AmB-R		WT
M-AmB	0.06 ± 0.01	2.15 ± 0.18	0.05 ± 0.01	1.69 ± 0.04	4.5 ± 0.4	6.7
H-AmB	1.53 ± 0.33	2.31 ± 0.32	0.05 ± 0.01	0.82 ± 0.03	39.8 ± 3.2	26.0
AmBisome®	1.76 ± 0.69	3.54 ± 0.10	1.73 ± 0.12	>100	36.5 ± 2.3	20.7
ME-AmB	0.88 ± 0.26	1.56 ± 0.01	0.22 ± 0.03	3.38 ± 0.08	9.0 ± 0.3	10.2
ME	28.01 ± 2.70	27.34 ± 0.24	6.82 ± 0.72	27.06 ± 0.52	22.8 ± 2.9	0.8

1 **Table 2:** *In-vivo* antileishmanial activity and acute toxicity of H-AmB and ME-AmB
 2 compared to M-AmB and AmBisome®. Mice were treated intravenously at 1 mg/kg
 3 equivalent AmB at Day 8, Day 10 and Day 12 post-infection.

	<i>In vivo</i> antileishmanial activity	<i>In vivo</i> toxicity					
	% Reduction of parasite burden	^a AST U/L	^a ALT U/L	^b CHO mM	^a CREA μM	^b ALP	^b URE
M-AmB	72	233.0	134.0	2.515**	19.5	225.5	10.70
H-AmB	78	189.5	171.5	2.575**	18.0	241.0	9.65
AmBisome®	83	242.5	167.0	*2.755	20.0	229.0	10.15
ME-AmB	78	224.5	169.5	2.415**	18.5	246.0**	8.35**
ME	*33	293.0	181.0	*2.710	16.0	225.0	*7.60**
Untreated	-	313.0	239.0	2.810	18.0	199.0**	7.40**

4

5 AST: aspartate aminotransferase. Normal value: 456 (U/L) (30).

6 ALT: alanine aminotransferase. Normal value: 304 (U/L) (30).

7 CHO : Cholesterol. Normal value: 3.5 mM (30).

8 CREA : Creatinine. Normal value: <18 μM (30).

9 URE : Urea. Normal value 7.4 mM.

10

* There was no significant difference in comparison to untreated (P>0.05)

** There was significant difference in comparison to AmBisome® (P<0.05)

^a P > 0.05

^b P < 0.05